The PREDICT Registry:
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
PreludeDx
3,000 participants
Feb 27, 2018
OBSERVATIONAL
Conditions
Summary
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Eligibility
Inclusion Criteria7
- Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
- Patient must have the DCISionRT test ordered during routine patient care.
- Patient must be eligible for or have recently completed breast conserving surgery.
- Patient must be eligible to receive radiation and/or systemic treatment.
- Patient must be 30 to 85 years old.
- Patient must have tumor size of less than 6 cm.
- Patient must have been diagnosed with DCIS within 120 days of consent.
Exclusion Criteria7
- Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing.
- Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget\'s disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast.
- Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS.
- Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer.
- Patient has a prior history of in-field radiation in the ipsilateral breast.
- Patient has had prior systemic endocrine or chemotherapy prior to testing.
- Patient is pregnant.
Interventions
Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03448926